Paul M Putora1, Dirk De Ruysscher2, Markus Glatzer3, Joachim Widder4, Paul Van Houtte5, Esther G C Troost6, Ben J Slotman7, Sara Ramella8, Christoph Pöttgen9, Stephanie Peeters2, Ursula Nestle10, Fiona McDonald11, Cecile Le Pechoux12, Rafal Dziadziuszko13, José Belderbos14, Corinne Faivre-Finn15. 1. Department of Radiation Oncology, Kantonsspital St. Gallen, Switzerland; Department of Radiation Oncology, University of Bern, Switzerland. 2. Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), The Netherlands. 3. Department of Radiation Oncology, Kantonsspital St. Gallen, Switzerland. 4. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria. 5. Department Radiation Oncology, Institut Bordet, Université Libre Bruxelles, Belgium. 6. OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Germany; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 8. Department of Radiation, Oncology, Campus Bio-Medico University, Rome, Italy. 9. Department of Radiation Oncology, West German Tumor Centre, University of Duisburg-Essen Medical School, Germany. 10. Department of Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany; Department of Radiation Oncology, University Hospital Freiburg, Germany. 11. Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK. 12. Department of Radiation Oncology, Gustave Roussy Cancer Campus, France. 13. Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland. 14. Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 15. Division of Cancer Sciences, University of Manchester & The Christie NHS Foundation Trust Manchester, UK.
Abstract
BACKGROUND: The role of prophylactic cranial irradiation (PCI) and thoracic radiotherapy (TRT) is unclear in resected small cell lung cancer (SCLC). METHODS: Thirteen European radiotherapy experts on SCLC were asked to describe their strategies on PCI and TRT for patients with resected SCLC. The treatment strategies were converted into decision trees and analyzed for consensus and discrepancies. RESULTS: For patients with resected SCLC and positive lymph nodes most experts recommend prophylactic cranial irradiation and thoracic radiotherapy. For elderly patients with resected node negative SCLC, most experts do not recommend thoracic radiotherapy or prophylactic cranial irradiation. CONCLUSION: PCI and TRT are considered in patients with resected SCLC and these treatments should be discussed with the patient in the context of shared decision-making.
BACKGROUND: The role of prophylactic cranial irradiation (PCI) and thoracic radiotherapy (TRT) is unclear in resected small cell lung cancer (SCLC). METHODS: Thirteen European radiotherapy experts on SCLC were asked to describe their strategies on PCI and TRT for patients with resected SCLC. The treatment strategies were converted into decision trees and analyzed for consensus and discrepancies. RESULTS: For patients with resected SCLC and positive lymph nodes most experts recommend prophylactic cranial irradiation and thoracic radiotherapy. For elderly patients with resected node negative SCLC, most experts do not recommend thoracic radiotherapy or prophylactic cranial irradiation. CONCLUSION: PCI and TRT are considered in patients with resected SCLC and these treatments should be discussed with the patient in the context of shared decision-making.
Authors: Markus Glatzer; Kari Tanderup; Angeles Rovirosa; Lars Fokdal; Claudia Ordeanu; Luca Tagliaferri; Cyrus Chargari; Vratislav Strnad; Johannes Athanasios Dimopoulos; Barbara Šegedin; Rachel Cooper; Esten Søndrol Nakken; Primoz Petric; Elzbieta van der Steen-Banasik; Kristina Lössl; Ina M Jürgenliemk-Schulz; Peter Niehoff; Ruth S Hermansson; Remi A Nout; Paul Martin Putora; Ludwig Plasswilm; Nikolaos Tselis Journal: Cancers (Basel) Date: 2022-02-11 Impact factor: 6.639